CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Tata Memorial Hospital Team Presents Biocon’s Nimotuzumab Study Results at ASCO Annual Meeting 2018

  • Posted by: BIOCON

Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of Ogivri™, the first biosimilar for Herceptin®, approved by US FDA

  • Posted by: BIOCON

Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr

  • Posted by: BIOCON

Kiran Mazumdar-Shaw #1 Business Captain in ‘The Medicine Maker 2018 Power List’

  • Posted by: BIOCON

Mylan and Biocon Receive Approvals from the European Commission and TGA, Australia for Semglee™ Biosimilar Insulin Glargine

  • Posted by: BIOCON

Mylan and Biocon Receive Positive CHMP Opinion for Semglee™, Biosimilar Insulin Glargine

  • Posted by: BIOCON

Biocon Q3FY18 Revenue at Rs 1092 Crore; EBITDA at Rs 256 Crore; Net Profit at Rs 92 Crore

  • Posted by: BIOCON

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars

  • Posted by: BIOCON

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs

  • Posted by: BIOCON

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>